A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-11

Study Completion Date

2017-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers

NCT02972255

Healthy Volunteers

COMPLETED PHASE1

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

NCT03182504

Gram-negative Bacterial Infections

COMPLETED PHASE1

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

NCT03840148

Urinary Tract Infections Acute Pyelonephritis

COMPLETED PHASE3

Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP

NCT02166476

Urinary Tract Infection Complicated Acute Pyelonephritis

COMPLETED PHASE3

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

NCT03687255

Urinary Tract Infections

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RO7079901 and Meropenem

Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.

Group Type EXPERIMENTAL

RO7079901

Intervention Type DRUG

Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.

Meropenem

Intervention Type DRUG

Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RO7079901

Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.

Intervention Type DRUG

Meropenem

Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Requiring hospitalization for IV antibacterial therapy for the treatment of presumed/confirmed cUTI (including pyelonephritis)
* Clinical signs and/or symptoms of pyelonephritis or a cUTI
* Urine culture taken within the 48 hours (hr) period immediately preceding the first dose of study drug contains greater than (\>)1x10\^5 colony forming units (CFU) per milliliter (CFU/mL) of a gram negative organism
* Negative urine pregnancy test result confirmed by a blood test
* Agreement to remain abstinent or use a contraceptive method

Exclusion Criteria

* Has a concomitant infection requiring antibacterial therapy, in addition to study drug
* Confirmed fungal urinary tract infection
* Moderate or severe renal impairment, or end-stage renal disease requiring renal replacement therapy or a recipient of a renal transplant
* Documented presence of immunodeficiency, or a severely immunocompromised condition or use of systemic immunosuppressant therapy
* Any rapidly progressing disease or immediately life-threatening illness, or other terminal illness or condition with high risk of mortality meaning that the participant is considered, in the opinion of the Investigator, unlikely to survive the study period
* Urinary tract surgery or clinically significant urogenital trauma in the one week immediately preceding study entry
* Urinary tract infection (UTI) symptoms potentially attributable to another process (sexually transmitted infections or prostatitis)
* Suspected or confirmed perinephric or intra renal abscess
* Complete obstruction of any portion of the urinary tract, or a permanent urinary diversion
* History of epilepsy, brain lesions or other significant neurological disorders
* Use of probenecid within the 7 days before enrollment
* Known history of clinically significant hypersensitivity or severe allergic reaction to meropenem or any other antibiotic
* Any other ongoing condition or disease, or clinically significant abnormalities in laboratory test results that the investigator considers would render the participant unsuitable for the study
* Women who are pregnant, planning to become pregnant, or lactating
* Participation in a clinical study of an investigational drug or device within one month prior to enrollment
* Prior enrollment in this study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No